Treatment of brain lymphoma with Lenalidomide, Methotrexate and Rituximab
- Conditions
- Health Condition 1: C858- Other specified types of non-Hodgkin lymphoma
- Registration Number
- CTRI/2020/10/028314
- Lead Sponsor
- Tata Memorial Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Patients with histologically proven PCNSL
Age > 18 years
ECOG PS <4
At least one bi-dimensionally measurable target lesion on MRI
Adequate bone marrow function with absolute leukocytes > 2000/mm3, neutrophil count (ANC) > 1000/mm3, haemoglobin > 8 g/dl and platelets > 100 000/mm3
Adequate liver function with Serum SGOT/AST or SGPT/ALT < 3.0 X Upper Limit of Normal ULN ; bilirubin < 1.5 X LNS
Creatinine clearance more than 60 ml/min
Men and women of child bearing age should agree to use reliable contraceptive
Neuropathy of >= grade 2 severity
HIV infection
Prior history of organ transplantation or other cause of severe immunodeficiency
History of heart disease and/or impaired cardiac function (ECG QTc >450msec, congenital long QT syndrome, history of ventricular tachyarrhythmia, ventricular fibrillation, congestive heart failure nyha iii/iv, uncontrolled hypertension)
Pregnancy or breast feeding Hypersensitivity to lenalidomide
Active hepatitis B and C
Prior history of malignancies within 3 years
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method